Comparing antidepressants by Relative Infant Dose for lactation safety
Placeholder lead: balancing maternal mental health treatment against infant milk exposure.
Placeholder body text: short paragraph on weighing maternal benefit versus infant exposure risk.
Placeholder body text: clinicians weigh RID, half-life, and maternal treatment history together.
Placeholder highlight: untreated depression itself carries real risk to mother and infant.
Placeholder lead: RID expresses infant dose as percent of weight-adjusted maternal dose.
Placeholder body text: infant dose (mg/kg/day) divided by maternal dose (mg/kg/day) times 100.
Placeholder body text: values under 10% are generally considered compatible with breastfeeding.
Placeholder highlight: RID is one input among several, not a sole decision rule.
Placeholder lead: sertraline consistently shows the lowest measured RID among SSRIs.
Placeholder body text: short elimination half-life limits steady accumulation in the infant.
Placeholder body text: widely studied and frequently recommended in lactation guidelines.
Placeholder highlight: largest evidence base of any SSRI in breastfeeding studies.
Placeholder lead: paroxetine is also low-RID; fluoxetine needs more caution.
Placeholder body text: low RID but shorter maternal half-life needs more frequent dosing.
Placeholder body text: norfluoxetine accumulates slowly in infants over weeks of exposure.
Placeholder highlight: fluoxetine reserved for cases with prior maternal response.
Placeholder lead: sertraline usually chosen; maternal response still guides therapy.
Placeholder body text: prior response to a specific SSRI can outweigh RID differences.
Placeholder body text: watch feeding, sedation, and growth after any drug is started.
Placeholder highlight: shared decision-making between clinician and mother is essential.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Sertraline | 0.4–2% RID | Short half-life, minimal active metabolite | Preferred first-line |
| Paroxetine | 1–3% RID | Low RID, shorter maternal half-life | Acceptable alternative |
| Fluoxetine | 6–9% RID | Long-lived active metabolite accumulates | Use with caution |